Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ensoma Inc.
Headquarters: Boston, MA, United States of America
Website: https://ensoma.com/
Year Founded: 2019
Status: Private
BioCentury | Aug 30, 2024
Emerging Company Profile
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
BioCentury | Nov 1, 2023
Finance
New VC Bioluminescence believes downturn offers ripe opportunity for platform investing
The firm’s founder, Kouki Harasaki, draws upon lessons from 2008 to guide investment thesis in current environment
BioCentury | Jul 14, 2023
Finance
July 13 Quick Takes: Apogee prices $300M IPO
Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia
BioCentury | May 17, 2023
Finance
May 16 Quick Takes: Leaps by Bayer, RA Capital back Boundless in $100M series C
Plus: Prevail, Scribe in gene editing deal and updates from Ensoma, NewLimit and Drug Farm
BioCentury | Jan 6, 2023
Deals
In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition
Ensoma raises $85M in series B led by Arix, 5AM and acquires gene editing company Twelve Bio
BioCentury | Sep 14, 2022
Emerging Company Profile
Capstan: bringing mRNA to in vivo CAR Ts
Capstan debuts with a Pfizer Ventures-led $102M series A, Penn technology to create in vivo cell therapies
BioCentury | Aug 11, 2022
Emerging Company Profile
Vector: targeted gene delivery with immune-shielded, high-capacity virus-like particles
Versant start-up using $30M series A to advance its gene delivery platform based on tech from Andreas Plückthun’s University of Zurich lab
BioCentury | Apr 9, 2022
Finance
5AM refuels, with eye toward new set of opportunities
As Levy, Soteropoulos join team, veteran early-stage investor has $750M in new funds to deploy
Items per page:
1 - 10 of 15